 The acetylpholvene alkylating agent LP184 retains nanomolar potency and non-smol cell lung cancer carrying otherwise therapy refractory mutations. More than 40% of non-smol cell lung cancer patients lack actionable targets and require non-targeted chemotherapeutics. LP184 is a next generation acetylpholvene class of prodrum. In this trending 2021 research paper published by AnkoTarget, researchers conducted a study to determine NS-CLC settings that LP184 might be an optimal treatment for. Read this study in more peer-reviewed oncology-focused research published by AnkoTarget.